|
Welcome to AMD Update!
It is estimated that 15 million people in the United States have age-related macular degeneration (AMD), with more than 1.75 million having advanced disease (defined as neovascular AMD or geographic atrophy); the number with advanced disease is expected to climb to almost 3 million by the year 2020. AMD is the leading cause of blindness in adults over 55 years of age.
AMD Update is a monthly e-newsletter dedicated to bringing to the ophthalmologist the latest and most useful clinical information and literature reviews on the management of AMD in a quick, easy to review format. The articles are written by a variety of authors in order to draw upon a wealth of expertise.
We hope that you will find the information timely and applicable to your practice, and that you will look forward to each issue.
Ingrid U. Scott, MD, MPH, Editor
We are pleased to have Ingrid U. Scott, MD, MPH as Editor of AMD Update.
Dr. Scott received both her medical degree and her master’s in public health degree from Johns Hopkins University. She completed ophthalmology residency training, fellowship training in vitreoretinal surgery and diseases and chief residency at the Bascom Palmer Eye Institute, University of Miami, where she stayed as Assistant Professor and then Associate Professor with tenure. Dr. Scott is currently Professor of Ophthalmology and Public Health Sciences at Penn State College of Medicine, where she also serves as the Ophthalmology Residency Program Director. Dr. Scott serves as Co-Chair of the Standard Care versus Corticosteroid for Retinal Vein Occlusion (SCORE) Study funded by the National Eye Institute, serves as the Chair of the Ophthalmic Technology Assessment Retina Panel of the American Academy of Ophthalmology, and has authored or co-authored over 200 peer-reviewed articles or book chapters.
Archived Newsletters:
» Issue 01 - Lucentis and Avastin: When to Use Which?
» Issue 02 - The Role of Intravitreal Triamcinolone Acetonide in AMD Management
» Issue 03 - Follow-up of AMD Patients Treated with Anti-VEGF Therapy: How to Monitor and Decide on Retreatment
» Issue 04 - Is There a Place for Combination Therapy in Neovascular AMD?
» Issue 05 - Should Lutein and Other Nutritional Supplements Be Given for the Therapy of Age-Related Macular Degeneration?
» Issue 06 - Monitoring for the Conversion of Dry to Wet Age-Related Macular Degeneration
» Issue 07 - Effect of Early Detection of Neovascular AMD on Visual Outcome
» Issue 08 - The Role of Fluorescein Angiography in AMD Management
» Issue 09 - How Long Should we Treat Patients with Anti-VEGF Therapy for Wet AMD Once the Lesion is Dry?
» Issue 10 - Artificial Vision
» Issue 11 - The Role of Photodynamic Therapy in AMD Management
» Issue 12 - Value-Based Medicine and Interventions for Neovascular Age-Related Macular Degeneration
» Issue 13 - Risk in AMD: Insight from Studies on Environmental Risk Factors, Genotype, and VEGF
» Issue 14 - Intravitreal Anti-VEGF Plus PDT Combination Therapy for Neovascular AMD: A Clinical Perspective
» Issue 15 - New OCT Devices: Implications for AMD Management
» Issue 16 - Triple Therapy in Exudative AMD
» Issue 17 - The Hidden Cost of Avastin AMD Therapy?
» Issue 18 - The Complex Role of Innate Immunity in Ocular Angiogenesis
» Issue 19 - Cell-based Therapies for AMD - a Cure on the Horizon?
» Issue 20 - Cataract Surgery in the Patient with AMD
» Issue 21 - A Combination of Anti-VEGF Therapy and Epi-retinal Radiation for the Treatment of Neovascular Age-related Macular Degeneration
» Issue 22 - Neovascular AMD: Not Only VEGF
» Issue 23 - Omega-3 Fatty Acid-Derived Resolvins and Protectins in Age-Related Macular Degeneration
» Issue 24 - AMD Research: Current Needs and Future Directions
» Issue 25 - Triple Therapy for the Treatment of CNV Due to AMD
» Issue 26 - The Use of Autofluorescence Imaging in AMD
» Issue 27 - Optical Coherence Tomography in Age-Related Macular Degeneration (AMD)
» Issue 28 - Age-Related Macular Degeneration and Cardiovascular Disease
» Issue 29 - Fluorescein Angiography in Age-Related Macular Degeneration
» Issue 30 - Vision-Related Function in Patients with Age-Related Macular Degeneration
» Issue 31 - VEGF-Trap Eye: What's the Evidence?
» Issue 32 - The Role of Vitamin A in the Progression of Dry AMD
» Issue 33 - Ciliary Neurotrophic Factor in the Treatment of Advanced Nonexudative Age-Related Macular Degeneration
» Issue 34 - Genetics of Age-Related Macular Degeneration
» Issue 35 - Managing the Patient with Bilateral Wet Macular Degeneration
» Issue 36 - Management of Subretinal Hemorrhage
» Issue 37 - Implantable Miniature Telescope for End-Stage Age-Related Macular Degeneration
» Issue 38 - Spectral-Domain Optical Coherence Tomography: Comparing Commercially Available Systems for Managing Patients with Age-Related Macular Degeneration
» Issue 39 - Cataract Surgery for Patients with Advanced Age-Related Macular Degeneration
» Issue 40 - Vitreoretinal Adhesion and Age-Related Macular Degeneration
» Issue 41 - Comparison of Two Doses of Intravitreal Bevacizumab as Primary Treatment for Subfoveal CNV Associated with AMD at 24 Months: The Pan-American Collaborative Retina Study Group
» Issue 42 - The "Treat and Extend" Dosing Regimen of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration
|
